DDX21 is a newly discovered RNA G-quadruplex (rG4) binding protein with no known biological rG4 targets. In this study we identified 26 proteins that are expressed at significantly different levels in cells expressing wild type DDX21 relative to an rG4 binding deficient DDX21 (M4). From this list we validate MAGED2 as a protein that is regulated by DDX21 through rG4 in its 5'UTR. MAGED2 protein levels, but not mRNA levels, are reduced by half in cells expressing only DDX21 M4. MAGED2 has a repressive effect on TRAIL-R2 expression that is relieved under these conditions, resulting in elevated TRAIL-R2 mRNA and protein in cells expressing only DDX21 M4, and rendering previously resistant cells sensitive to TRAIL mediated apoptosis. Our work identifies the role of DDX21 in regulation at the translational level through biologically relevant rG4 and shows that MAGED2 protein levels are regulated, at least in part, by a rG4 forming potential in their 5'UTRs.
Introduction
DDX21 is an RNA helicase protein with a diverse set of biological functions. It plays important roles in ribosomal RNA biogenesis 1,2 by coordinating Pol I transcription and association of late acting snoRNAs with pre-ribosomal complexes 3, 4 . DDX21 has also been implicated in double stranded RNA sensing and anti-viral response [5] [6] [7] [8] as well as epigenetic silencing of genes 9 .
Abnormal levels of DDX21 protein has been observed in colorectal 10 and breast cancers 11 (where it has been correlated with disease free survival, possibly mediated by regulating c-Jun activity and rRNA biogenesis 12, 13 ) as well as in schizophrenic patients, making it a potential therapeutic target. Recently, we have shown that DDX21 can bind and unwind guanine-quadruplexes (rG4s) and affect the translation of a reporter construct with a rG4 in its 5' UTR 14 . This activity is mediated by an evolutionarily conserved region repeat region (F/PRGQR) in its C-terminus that preferentially interacts with the backbone of RNA rG4s 15 . It is unlikely that such an activity would exist and persist in an enzyme if there were no biological need for it. Recent iCLIP data using anti-DDX21 antibodies showed that ~35% of DDX21 bound RNA is mRNA 16 , yet no rG4 targets of DDX21 are currently known.
RNA rG4s are four stranded structures of RNA that form in regions rich in guanines. When four guanines align in a plane they can form an extended hydrogen bonding network called a guanine tetrad. Successive guanine tetrads can pi stack on top of one another to form a stable rG4
structure. The canonical rG4 forming sequence is GGG(N1-7)GGG(N1-7)GGG(N1-7)GGG, where (N1-7) represents a short loop of 1-7 nucleotides. However, longer loops as well as interrupted Gtracts have also been shown to still allow for rG4 formation. Canonical rG4s 17 as well as irregular rG4s 18 present in mRNA have been shown to modulate translation of the mRNA, either through stalling of scanning pre-initiation complexes on 5' UTRs 17 , by alternative splicing mediated by rG4s [19] [20] [21] , or direction of miRNA binding to 3' UTRs 22, 23 . A transcriptome-wide sequencing approach that exploits the ability of RNA rG4s to cause reverse transcriptase stop (rG4-seq) has identified thousands of putative quadruplexes, many of which are non-canonical rG4s that would likely be missed by bioinformatic searches 24 .
In our current study we use proteomic mass spectrometry (MS) to compare the levels of proteins in cell populations that are expressing wild type DDX21 or a DDX21 mutant with impaired rG4 binding and unwinding abilities (DDX21 M4). We compare this list of candidate proteins to the rG4-seq database, finding a significant enrichment for rG4 containing mRNA in our list of candidate proteins, and confirm the interaction of DDX21 with the mRNA of candidate proteins by RIP-qPCR experiments. One of the promising candidate proteins, Melanoma associated antigen D2 (MAGED2) protein abundance is significantly reduced in the cells expressing DDX21 M4 and not the WT DDX21. MAGED2 has been implicated in cancer progression and resistance to treatment of human breast cancers, specifically, MAGED2 acts as a transcriptional repressor of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor 2 (TRAIL-R2) mRNA 25, 26 . For decades TRAIL has been studied as a potential natural anti-tumoral protein with the ability to selectively trigger cell death in cancer cells through interactions with surface expressed receptors DR4 and DR5 (TRAIL-R1 and TRAIL-R2) 27 . TRAIL resistance occurs in breast cancer cells when the death receptors DR4 and DR5 (TRAIL-R2) are no longer expressed on the cell surface 28 . TRAIL sensitization is emerging as a novel therapeutic target for treating resistance breast cancers 29, 30 . We confirm by qPCR and Western blot that regulation of MAGED2 by DDX21 also affects the downstream target of MAGED2, TRAIL-R2, and imparts a sensitivity to TRAIL mediated apoptosis.
To further investigate the link between rG4 and MAGED2 we synthesized a mutant version of the MAGED2 5' untranslated region (UTR) (where the G4 is predicted to be) with G to C mutations disrupting all runs of 3 or more consecutive guanines. A side by side comparison of the effect of wild-type and mutant 5' UTR in a luciferase assay reveals a loss of regulatory effect with the mutant UTR. We provide direct evidence of rG4 formation in the in vitro transcribed wild-type 5' UTR using an RNA G4 specific fluorescent probe, Thioflavin T (ThT), and a modified reverse transcription stop method that demonstrates rG4 unwinding by DDX21.
Together these results indicate that DDX21 regulates translation of MAGED2 mRNA in a rG4 dependent manner and contributes to sensitization to TRAIL mediated apoptosis.
Results

Identifying putative G4 targets of DDX21
To look for potential G4 targets of DDX21 we wanted to compare cell populations expressing a wildtype and a mutant (M4) DDX21 with impaired G4 binding. The M4 mutant contains a PRGQR to YEGIQ mutation in the C-terminal repeat region of DDX21 that has been previously shown to disrupt rG4 binding and unwinding activities 14 . Differences between the wildtype DDX21 recovery (WT) and M4 DDX21 recovery experiments should be due to differences in DDX21 G4 interactions. Briefly, HEK293T cells were first transfected vector expressing either WT or M4 DDX21. Following this, endogenous DDX21 was depleted by siRNA knock-down.
Using label-free whole-cell proteome analysis we identified 26 candidate proteins ( Figure 1A) whose expression level was significantly different between the M4 and WT samples. The data in Figure 1A is represented as the ratio of the amount of a protein detected in the M4 vs WT Figure 1B ).
To determine if the change in protein levels could be due to altered mRNA level we performed qPCR on RNA extracts from the samples ( Figure S1 ). While some mRNA levels were found to be significantly different than negative control samples (PSMD11, HNRNPA3, TMPO, CAPZA, formation. RIP-qPCR experiments using anti DDX21 antibodies showed significant enrichment (3 standard deviations above GAPDH) for 6 of the candidate proteins' mRNA ( Figure 2 ). Of these 6 genes, 3 had predicted rG4s in the 5'UTR and 3 had predicted rG4s in the coding sequence (CDS). Interestingly, this distribution is quite the opposite of what was observed in the rG4-seq database in general, they report approximately 62% of the rG4s found to be in the 3'UTR and the remainder to be 16% 5'UTR and 20.6% CDS.
The large enrichment of proteins with rG4 containing mRNA in our list indicates there is good potential for direct regulatory effects to be discovered. The DDX21-IP allows us to further narrow our search by only focusing on the mRNA that are preferentially co-precipitated with DDX21. 
DDX21 regulates TRAIL-R2 expression and protects cells from TRAIL mediated apoptosis
MAGED2 has been shown to regulate TRAIL-R2 protein and mRNA levels in a p53 dependent manner 25, 26, 31 . To test whether the changes in MAGED2 level from DDX21 knock-down or M4 mutant could affect TRAIL-R2 we performed qPCR on RNA extracted from our knock-down recovery experiments. The RNA from the HEK293T cells showed no difference in mRNA levels of p53, MAGED2 or TRAIL-R2 ( Figure S1 ). Since this pathway has been shown to be p53 dependent, and HEK293T have p53 suppressed by the SV40 large T antigen 32 , we repeated the experiment with MCF-7 cells that have wild-type p53 33 . In MCF-7 cells we saw an increase in TRAIL-R2 mRNA levels upon DDX21 knock-down, but not p53 or MAGED2 ( Figure 4A ). 
MAGED2 TV2 is most enriched transcript variant by RIP-rt-qPCR
The failure of the M4-DDX21 mutant to recover to the wild-type MAGED2 level is indicative of the involvement of rG4s in the regulation. MAGED2 has three alternative splice variants that result in different 5'UTR, but with no change to protein coding sequence. Though the variants share a conserved 31 nucleotides before the start codon, their 5' regions vary in length and sequence from 125nt for TV1, 233nt for TV2 and 193nt for TV3. All transcript variants have high rG4 forming potential, TV1 has 5 runs of 3 consecutive guanines, TV2 has 9 runs of 3 consecutive guanines and TV3 has 8 runs of 3 consecutive guanines. To decipher which of these transcript variants could be contributing to regulation of MAGED2 we first returned to our DDX21-RNA-IP samples and looked for differences in enrichment between primer sets specific for individual transcript variants ( Figure 5A ). While a primer set that doesn't discriminate between MAGED2 transcript variants is enriched 4.6-fold, TV1 and TV3 were only enriched 1.7 and 2.2-fold, respectively. TV2 has the highest fold enrichment with a 5.5-fold change, indicating it is preferentially interacting with DDX21 in cell lysate.
MAGED2 5'UTR Luciferase Assays
As the strongest candidate for DDX21 interaction we site specifically mutated all 9 runs of guanines from TV2 so that there are never more than two consecutive guanines (TV2m). TV2
and TV2m were cloned into the dual-luciferase vector, PsiCheck-2, immediately 5' of the hRLuc gene such that they would be transcribed as a 5'UTR. A common criticism of these assays is that the efficient transcription from the promotor on the luciferase vector results in levels of hRLuc mRNA that far exceed the levels of mRNA of the endogenous mRNA. In the context of G4 regulation, the increased number of G4s could exceed the capacity of the cellular G4 helicase proteins to unwind them 34 . In order to mitigate this effect, we truncated the CMV promotor in front of our 5'UTR to reduce the level of reporter mRNA being made. HEK293T cells were treated as they were for the MS experiments and at 48 hours post endogenous DDX21 knockdown they were transfected with the dual-luciferase reporter vector.
In the experiments with the wild type TV2 5' UTR, DDX21 siRNA knock-down significantly (P<0.05) reduced the luciferase activity from the levels observed in the negative control cells ( Figure 5B ). This effect was rescued by overexpression of the WT DDX21 but not M4. The luciferase activity from the M4 samples was also significantly reduced compared to negative control and WT samples, but not significantly different than the DDX21 knock-down samples. In the experiments with TV2m or an "empty vector" (no 5' UTR added), no significant change in luciferase activity was detected between NC, KD, WT or M4 samples. To begin probing whether the MAGED2 TVs form rG4, we introduced an RNA rG4 stabilizing ligand carboxypyridostatin (cPDS) into the luciferase assays. Cells that were otherwise untreated were treated with cPDS immediately prior to transfection of the reporter vector. Compared to the samples that were not treated with cPDS, the treated samples had only 15% of the luciferase activity from the vector with the intact TV2 5'UTR. Whereas, the TV2m reporter construct showed no change in luciferase expression in the presence of cPDS. The empty vector samples were similarly unaffected by cPDS with the exception of one replicate having increased luciferase activity, adding significant error to the average luciferase activity.
In Vitro evidence of rG4 formation
To further validate rG4 formation the TV2 and TV2m were in vitro transcribed from the PsiCheck-2 vector and purified by size exclusion chromatography. To confirm the possibility of direct interactions with DDX21 and to ascertain any possible specificity of DDX21, electrophoretic mobility shift assays (EMSA) were performed ( Figure S2 ) with recombinant purified DDX21 from E.coli. At the highest DDX21 concentration (1000nM) both RNA completely shifted to higher molecular weight complexes. Densitometric analysis using the FluorChem Q software allowed for fitting of the EMSA to a binding model (Table 1) .
Recombinant purified DDX21 showed marginally higher affinity for TV2 vs TV2m (100nm vs 300nm)
TV2 and TV2m were assayed for rG4 formation by ThT, a fluorescent probe for RNA rG4 formation 35, 36 . When ThT is bound to rG4 it exhibits enhanced fluorescence. rG4 conformations are stabilized by monovalent cations, with K+ being the best at stabilizing rG4 and Li+ having destabilizing effects, but alternate conformations of RNA are not greatly affected by these cations 37 . By comparing ThT fluorescence in the presence of rG4 stabilizing and destabilizing cations we strengthen the evidence that enhanced fluorescence is due to rG4 formation. TV2
induces significantly more fluorescence from ThT than TV2m, furthermore, the large difference on ThT fluorescence, typically emitting 10-30% the amount of fluorescence compared to TV2 at a given concentration; together with a lack of significant difference between TV2m in K+ or Li+ containing samples this indicates that TV2m does not form a rG4.
Finally, we used a modified reverse-transcriptase stop assay (rt-stop) to demonstrate structural differences between TV2 and TV2m. The principle of this assay is that a structured RNA will not be efficiently reverse transcribed and result in a mixture of full length and aborted transcripts.
By comparing the amount of reverse transcriptase stopping TV2 and TV2m we can infer differences in their structure. Briefly, reverse transcription reactions were performed on equal amounts of both of the in vitro purified RNA at 37⁰C for 20 minutes. After purification of cDNA, qPCR was used to amplify the cDNA and the cycle at which the qPCR signal reached its critical threshold Ct was taken as an indicator of the efficiency of cDNA synthesis. We used two primer sets to probe the efficiency of reverse transcription of TV2 and TV2m RNA. One primer set spanned the entire RNA and the other primer set only amplified the 3' region of the RNA after the last run of 3 consecutive guanines and where the two RNA share the same sequence.
Reverse transcription products that stopped due to structures in the region of mRNA containing the G tracts would not be detected with the primer spanning the full UTR, whereas they could still be amplified by the second primer set making it a useful control for the amount of RNA input. For TV2m, both primer sets gave comparable Ct values, resulting in a ΔCt of 0.05 ± 0.48 cycles between them ( Figure 6B ). For the wild-type TV2 the Ct was reached 3.06 ± 0.35 cycles later with the primer set spanning the full UTR than the internal control primer set.
Identification of rG4 location and evidence of rG4 unwinding by DDX21
To begin to characterize the rG4 forming sequence in the MAGED2 TV2 UTR we performed reverse transcription reactions on TV2 and TV2m using fluorescently labelled primers, this allowed us to visualize the rt-stop products on by denaturing PAGE ( Figure 7A ). The full length 234nt cDNA was observed in both TV2 and TV2m reverse transcription reactions, while a shorter, ~115nt cDNA was only observed with TV2 ( Figure 7B ), This shorter cDNA is likely the result of a stalled reverse transcriptase that encountered significant secondary structure. From the length of this rt-stop product we can locate the position of the interfering structure in theTV2
RNA. The rt-stop is immediately prior to a sequence with high rG4 forming potential:
When recombinant purified DDX21 is added to the reverse transcription reaction with the TV2
RNA we observe a two-fold decrease in rt-stop products by densitometric analysis, remarkably consistent with the change in MAGED2 protein we see with DDX21 knock-down and M4 recovery ( Figure 1A & Figure 3 ). This data indicates that DDX21 can unwind or destabilize the rG4 within TV2 enough to significantly alter the reverse-transcription efficiency. 
Discussion
Recently we discovered DDX21 to be an RNA rG4 binding protein that has the ability to destabilize rG4s 14 . Until now studies have focused on model RNA systems and there are no rG4s that DDX21 is known to interact with endogenously. A unique aspect of our study unique is the implementation of an RNA helicase protein that has been site-specifically mutated to have reduced affinity for RNA G-quadruplexes. By comparing differences in the whole-cell proteome in cell populations with either a wild type or mutant helicase protein we are able to discern differences that are due to the reduced affinity for RNA G-quadruplexes. We use this tool to identify, for the first time, potential biologically relevant G-quadruplex targets of the RNA helicase protein DDX21. This method could also be adapted to the study of other moonlighting proteins where the biochemical data exists to allow for specific mutations that only affect one of its activities.
From the list of proteins affected by replacement of wildtype DDX21 with M4 we validated MAGED2 by Western blot, a 2-fold decrease in the M4 DDX21 sample by MS is observed.
MAGED2 has been shown to interact with p53 and affect transcription and protein levels of TRAIL-R2. It has been hypothesized that increased MAGED2 expression is a mechanism to selectively inactivate certain P53 targets (i.e. TRAIL-R2). Previous studies have shown that a decrease in MAGED2 protein results in upregulation of P53 and TRAIL-R2 at the mRNA and protein level. 25, 31 . We observed a similar effect in MCF-7 cells, revealing a pathway whereby WT DDX21 can facilitate MAGED2 translation which in turn blocks TRAIL-R2 expression.
Interestingly, replacement of the WT DDX21 for the M4 mutant results in decreased MAGED2
protein and in turn an increase in TRAIL-R2 expression, indicating that G4 binding and unwinding is important for efficient translation of MAGED2 mRNA. This increase in TRAIL-R2 expression is significant enough to allow for TRAIL induced apoptosis in MCF-7 cells depleted of DDX21 or expressing only the M4 DDX21.
After determining that DDX21 preferentially binds the TV2 5'UTR, by DDX21-IP and rt-qPCR, we investigated a mutant version of TV2 in which all runs of GGG had been changed to GCG (TV2m). The TV2m 5'UTR was not impacted by DDX21 knock-down or recovery, whereas TV2 had decrease luciferase activity with depleted DDX21, M4 DDX21 and in the presence of rG4 stabilizing dye cPDS. Furthermore, in vitro transcribed and purified TV2m shows reduced affinity for DDX21 by EMSA and does not demonstrate the K+ sensitive ThT fluorescence response that TV2 does. These data provide strong evidence for rG4 formation in the MAGED2 TV2 5' UTR.
Using an adapted reverse transcription stalling assay, modelled off the recently developed highthroughput rG4-seq method 24 , we demonstrate that TV2 contains a structural element, not present in TV2m, that impedes reverse transcription efficiency. By adding DDX21 into the reverse transcription reaction we turn this easy to perform rG4 detection method into a functional helicase assay. A major downfall of the current methods used to probe G4 helicase activity is the lack of sequence context surrounding the G4 structure. In this assay we can convincingly show rG4 disruption in the context of a full length 5' UTR, in this case, where the rG4 is in the center of a 234 nucleotide RNA. In our opinion this is a significant advancement from the trap-based assays 38 , tetramolecular assays 39 and nuclease sensitivity assays 14 used previously. Together these data provide strong evidence that DDX21 can regulate MAGED2 translation via a rG4 in its 5'UTR.
Targeting of rG4 regulated pathways is an emerging area of therapeutic potential for fighting cancer 40, 41 and sensitization of TRAIL-resistant breast carcinoma to TRAIL mediated apoptosis is a current therapeutic target 27, 29, 30 . Our data underline the potential for the integration of rG4 therapeutics with an existing cancer treatment interest. Current research suggests that DDX21 has a unique specificity for certain rG4s that may be dependent on loop sequence 14, 42 . Further work aims to identify the structure of the TV2 rG4 that DDX21 is recognizing, deciphering the specificity of DDX21 may potentially allow for the design of small molecules that specifically block its action.
Materials and Methods
Cell Culture and Reagents
The HEK293T cell line was a gift from Dr. Thomas Klonisch and the MCF-7 cell line was a gift 
In-gel digestion
Protein lanes were visualized by Coomassie Blue staining prior to whole-lane excision. Each lane was subsequently cut into 15 equal bands, with each band corresponding to a region of the gel containing proteins of a distinct molecular weight range. Each of the gel fractions was subjected to in-gel tryptic digestion as previously described 41 ; the resulting extracted peptides were then dried and suspended in 60 µL of 0.2% formic acid in 5% ACN. For data analysis, raw data files corresponding to samples comprising an entire gel lane were grouped together and searched using Proteome Discoverer 1.4.1.14's SEQUEST search algorithm using the reviewed, nonredundant H. sapien complete proteome retrieved from UniprotKB. Search parameters were identical to as previously reported 42 . During data processing, the "Precursor Ion Area Detector" node of Proteome Discoverer 1.4.1.14's SEQUEST workflow editor was implemented to quantify the extracted ion chromatogram for each protein identified from the raw data. Searched results were filtered using a minimum of two medium confidence peptides per protein.
LC-MS/MS Analysis
Protein-RNA cop-immunoprecipitation and RT-qPCR
Native RNA immunoprecipitations were performed on one 150 mm dish of HEK293T cells as previously described 45 using anti-DDX21 antibody (ProteinTech 15252-1-AP). RT-qPCR analysis was performed on Applied Biosystems StepOnePlus instrument with the RNA to Ct One-step RT-qPCR kit (Thermo Fisher Scientific) according to manufacturer's instructions. To determine fold enrichment, RNA extracted from the total cell lysate using the GeneJET RNA purification kit (Thermo Fisher Scientific) was used to IP to serve as a reference sample. 25 ng of template RNA was used in all RT-qPCR reactions.
Western blots
For each sample, 50 µg of protein in 1X SDS-PAGE load dye was loaded onto a 10% SDS- degrees Celsius in TBST+ 5% milk, GAPDH and tubulin primary antibodies were incubated for 1 hour at room temperature in TBST+5% milk. Three sequential 5-minute washes with 5% TBS-T were followed by 1-hour incubation with secondary antibodies (1:10000) in TBST+5% milk and then 4 more 10-minute washes with TBS-T. Prior to imaging with the FluorChem Q system (Protein Simple), 1 ml of Illuminata Forte Western HRP substrate (EMD Millipore) was added to the blots. Due to weak signal from some antibodies a uniform adjustment to the brilliance was made using Inkscape V 0.91.
Annexin V staining & TRAIL treatment
MCF-7 cells were treated as described in the DDX21 siRNA knock-down and recovery section. Samples were then diluted to 500 µl with 1X Annexin-binding buffer and kept on ice. Annexin V binding was measured using the BD FACSCalibur platform and analyzed using the BD CellQuest Pro software (BD Biosciences, San Jose, CA), 10,000 cells from each sample were analyzed and each sample performed in biological triplicate.
Luciferase assays
For luciferase assays, HEK293T cells were treated as described in the DDX21 siRNA knockdown and recovery section scaled down to a 6 well dish sample size. Half of the cells were used for RNA purification using the GeneJET RNA purification kit (Thermo Fisher Scientific) and the other half used in the luciferase assay. The Dual-Glo Luciferase Assay system (Promega, Madison Wi, USA) was used according to manufacturer instructions, luminescence was measured for 10 seconds using the (Pelka's instrument) and each sample performed in at least biological triplicate. To control for transfection efficiency, luminescence from the hRluc protein, under control of the 5'UTR cloned into the NheI site was normalized to the signal from the hluc protein for each sample. Each sample was then normalized to the average value of the negative control samples.
Cloning
The pcDNA3 vector was used to create a CMV promotor lacking nucleotides between 208 and 746, this was then cloned into the BglII and NheI sites of the psiCHECK-2 vector, removing the SV40 promotor. 5'UTRs of MAGED2 TV2 and TV3 were amplified by RT-PCR from RNA isolated from human testes tissue purchased from Takara Bio (Mountain View, CA). The 5'UTR of TV1 was amplified from a DNA fragment purchased from Genscript. Each TV was amplified using primers that contain restriction enzyme sites for NheI and cloned into the psiCHECK-2 vector. The cDNA that encodes the human DDX21 protein, isoform 1, was amplified by PCR using DNA primers that were designed to encode an NheI and NotI restriction enzyme sites and cloned into the pET28b expression vector.
In vitro transcription and protein purification
The 5'UTRs of each transcript variant were transcribed and purified in vitro as previously imidazole. Elution fractions were dialyzed against 20 mM Tris pH 7.5, 300 mM NaCl, 10%
glycerol, 2 mM DTT, and stored at 4⁰C.
Electrophoretic Mobility Shift Assays
DDX21, or an equal volume of protein storage buffer (20 mM Tris pH 7.5, 300 mM NaCl, 10% glycerol, 2 mM DTT) was added to the binding reactions in a 1:1 serial dilution, with the first condition containing no DDX21. Binding reactions were performed in 50 mM Tris-acetate, pH 7.8, 100 mM KCl, 10 mM NaCl, 3 mM MgCl2, 70 mM glycine, 10% glycerol, 0.05 mg/mL bovine serum albumin (BSA) for 10 min at room temperature and resolved by native Tris-borate EDTA (TBE) 8% polyacrylamide gel electrophoresis (TBE-PAGE) for 150 minutes at 75V. The
RNAs were then stained with the fluorescent nucleic acid dye SYBR Gold and imaged on a Fluorchem Q imaging system using the Cy2 excitation LEDs and emission filters (Protein Simple, San Jose CA).
Thioflavin T assays
In a 96-well plate, the in vitro transcribed RNA was serially diluted 3:1 with 20 mM Tris pH 7.5, 
Reverse Transcriptase Stop Assays
First strand synthesis of cDNA from 50ng of in vitro transcribed 5'UTR of TV2 and TV2m was performed in a 20µL reaction using 1µM reverse primer, 500µM dNTPs, 4µL 5X RT Buffer Reactions were performed at 37⁰C for 60 minutes before heating at 85⁰C for 5 minutes to inactivate the RT. To remove DNA:RNA heteroduplex from the reactions, the cDNA samples were treated with RNAse H for 20 minutes at 37⁰C. After RNAse H digestion, cDNA was mixed with an equal volume of denaturing RNA load dye (95% formamide, 0.01% SDS, 0.5 mM EDTA, 0.025% (w/v) Orange G), heated at 95⁰C for 5 minutes, and resolved by TBE-urea PAGE with 12% acrylamide gels. Cy5 labelled RNA ladder was prepared as described previously 47 with the addition of Cy5-labbeled TV2 for the additional 234nt band. Reverse transcription products and ladder were visualized with Cy5 excitation and emission filters.
